Share this video  

ASCO GI 2021 | Phase I study of OBP-301 for locally advanced esophageal cancer

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale of an ongoing NRG Oncology NRG-GI007 Phase I study of telomelysin and chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery. Telomelysin is a conditionally-restricted, replication-competent adenovirus that adds a hTERT gene promoter, replicating only in tumor cells to cause lysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).